WAVEMAN · COMPANY

FMC · Fmc Corp

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

FMC

Name: FMC CORP (FMC) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

FMC CORP

PHARMA & BIOTECH · CHEMICALS & ALLIED PRODUCTS · CIK 0000037785

CONGRESS · 1☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

202

13F, latest reported quarter

REVENUE GROWTH

-18.3%

XBRL, annual

NET MARGIN

-64.6%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

202 funds added or opened last quarter

more than 87% of Pharma & Biotech

REVENUE

-18.3% year over year

below 74% of Pharma & Biotech

MARGIN

-64.6% net margin

below 60% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

21.3% of shares outstanding short · 6.4 days to cover · settled 2026-07-31

more than 96% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

202 funds added or opened positions in the latest 13F quarter, of 412 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -64.1%

-64.1%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 202 funds added last quarter, 1 Congress member(s) bought in 12 months. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for FMC CORP in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

BARRY MICHAEL F

Director

BUY

2026-03-04

18,072.19

$249.9K

Raines John Mitchell

Director

BUY

2025-11-13

7,000.0

$96.4K

DAVIDSON CAROL ANTHONY

Director

BUY

2025-11-05

10,000.0

$136.0K

Scanlan Jacqueline

Executive VP & Chief HRO

SELL

2025-09-29

3,790.0

$128.9K

Scanlan Jacqueline

Executive VP & Chief HRO

SELL

2025-08-18

1,510.0

$56.6K

40 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 35 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

21,535,604.0 sh

$247.7M

AQR CAPITAL MANAGEMENT LLC

8,021,709.0 sh

$91.1M

VANGUARD PORTFOLIO MANAGEMENT LLC

7,719,466.0 sh

$88.8M

STATE STREET CORP

6,508,595.0 sh

$75.4M

VANGUARD CAPITAL MANAGEMENT LLC

5,758,841.0 sh

$66.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco S&P SmallCap Materials ETF

$377.5K POSITION · AS OF 2026-02-28

2.0%

EP Emerging Markets Fund

$2.3M POSITION · AS OF 2026-04-30

1.7%

Brookstone Dividend Stock ETF

$1.2M POSITION · AS OF 2026-02-28

1.2%

Invesco Zacks Multi-Asset Income ETF

$1.3M POSITION · AS OF 2026-04-30

1.1%

S&P SmallCap 600 Pure Value Fund

$90.7K POSITION · AS OF 2026-03-31

0.9%

Invesco S&P Smallcap 600 Pure Value ETF

$1.9M POSITION · AS OF 2026-04-30

0.7%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$3.5B	$4.2B	$4.5B	$5.8B
GROSS PROFIT	$1.3B	$1.6B	$1.8B	$2.3B
OPERATING INCOME	$-1.6B	$506.5M	$555.6M	$1.1B
NET INCOME	$-2.2B	$341.1M	$1.3B	$736.5M
EPS (DILUTED)	-17.88	2.72	10.53	5.81
CASH	$584.5M	$357.3M	$302.4M	$572.0M
LONG-TERM DEBT	$2.8B	$3.0B	$3.0B	$2.7B
BUYBACKS	$0	$0	$75.0M	$100.0M
DIVIDENDS PAID	$291.3M	$290.6M	$290.5M	$267.5M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE